Mainstream

Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide

Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide

Post Contentnvo, lly, ivbiy, ivbxfRead More

You might also be interested in reading New Memecoin Sensation Neiro Hits $200 Million Market Cap In Four Days.

June 30, 2025
In Mainstream